LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?

[1]  M. Farrer,et al.  LRRK2 mutations are a common cause of Parkinson's disease in Spain , 2006, European journal of neurology.

[2]  Irene Litvan,et al.  Lrrk2 and Lewy body disease , 2006, Annals of neurology.

[3]  T. Meitinger,et al.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.

[4]  T. Nägele,et al.  Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. , 2005, Brain : a journal of neurology.

[5]  A. Brice,et al.  Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function , 2005, Journal of neurochemistry.

[6]  A. Singleton,et al.  Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. , 2005, Brain : a journal of neurology.

[7]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[9]  M. Farrer,et al.  Lrrk2 pathogenic substitutions in Parkinson's disease , 2005, Neurogenetics.

[10]  M. Farrer,et al.  LRRK2 mutations in Parkinson disease , 2005, Neurology.

[11]  K. Lim,et al.  Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. , 2005, Human molecular genetics.

[12]  R. Hilker,et al.  Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers , 2005, Annals of neurology.

[13]  Hongjun Song,et al.  Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death , 2005, The Journal of Neuroscience.

[14]  Andrew J Lees,et al.  Atypical unclassifiable parkinsonism on Guadeloupe: An environmental toxic hypothesis , 2005, Movement disorders : official journal of the Movement Disorder Society.

[15]  A. Dürr,et al.  LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. , 2005, American journal of human genetics.

[16]  M. Spillantini,et al.  Alpha‐synuclein dysfunction in Lewy body diseases , 2005, Movement disorders : official journal of the Movement Disorder Society.

[17]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[18]  M. Farrer,et al.  LRRK2 R1441G in Spanish patients with Parkinson's disease , 2005, Neuroscience Letters.

[19]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[20]  Mark R Cookson,et al.  The biochemistry of Parkinson's disease. , 2005, Annual review of biochemistry.

[21]  Pasko Rakic,et al.  Mixed lineage kinase–c‐jun N‐terminal kinase signaling pathway: A new therapeutic target in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[22]  Kazuko Hasegawa,et al.  An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family , 2005, Annals of neurology.

[23]  M. Feany,et al.  α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.

[24]  Timothy Lynch,et al.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.

[25]  Tom Robinson,et al.  Vascular parkinsonism--an important cause of parkinsonism in older people. , 2005, Age and ageing.

[26]  J. Tschopp,et al.  The RIP kinases: crucial integrators of cellular stress. , 2005, Trends in biochemical sciences.

[27]  C. Ross,et al.  Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation , 2005, The Journal of Neuroscience.

[28]  Nicholas W Wood,et al.  A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.

[29]  Tatiana Foroud,et al.  Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease , 2005, The Lancet.

[30]  Vincenzo Bonifati,et al.  A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease , 2005, The Lancet.

[31]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[32]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[33]  M. Chesselet,et al.  Alpha-synuclein and transgenic mouse models , 2004, Neurobiology of Disease.

[34]  Giuseppe Battaglia,et al.  Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Farrer,et al.  α‐Synuclein promoter confers susceptibility to Parkinson's disease , 2004 .

[36]  M. Farrer,et al.  Linkage disequilibrium and association of MAPT H1 in Parkinson disease. , 2004, American journal of human genetics.

[37]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[38]  J. Schulz.  Neuronal pathology in Parkinson’s disease , 2004, Cell and Tissue Research.

[39]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[40]  D. Labarthe,et al.  Incidence of Amyotrophic Lateral Sclerosis and of the Parkinsonism-Dementia Complex of Guam, 1950–1989 , 2004, Neuroepidemiology.

[41]  C. Haass,et al.  How does parkin ligate ubiquitin to Parkinson's disease? , 2004, EMBO reports.

[42]  W. Kamphorst,et al.  Phenotypic Variation in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 , 2004, Dementia and Geriatric Cognitive Disorders.

[43]  David W. Miller,et al.  α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication , 2004, Neurology.

[44]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[45]  G. Mardon,et al.  Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress , 2004, Development.

[46]  Joachim Klose,et al.  Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.

[47]  P. Lockhart,et al.  Parkin genetics: one model for Parkinson's disease. , 2004, Human molecular genetics.

[48]  John Hardy,et al.  CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation , 2004 .

[49]  D. Goldstein,et al.  UCHL1 is a Parkinson's disease susceptibility gene. , 2004 .

[50]  Steven P. Gygi,et al.  CHIP-Hsc70 Complex Ubiquitinates Phosphorylated Tau and Enhances Cell Survival* , 2004, Journal of Biological Chemistry.

[51]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[52]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[53]  Eugene M. Johnson,et al.  Mixed-lineage kinases: a target for the prevention of neurodegeneration. , 2004, Annual review of pharmacology and toxicology.

[54]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[55]  Jeffrey H. Kordower,et al.  The role of α-synuclein in Parkinson's disease: insights from animal models , 2003, Nature Reviews Neuroscience.

[56]  R. Nussbaum,et al.  Functional analysis of intra-allelic variation at NACP-Rep1 in the α-synuclein gene , 2003, Human Genetics.

[57]  P. Davies,et al.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms , 2003, Journal of neurochemistry.

[58]  H. Payami,et al.  A linkage study of candidate loci in familial Parkinson's Disease , 2003, BMC neurology.

[59]  Jeremy N. Skepper,et al.  α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.

[60]  S. Fahn.  Description of Parkinson's Disease as a Clinical Syndrome , 2003, Annals of the New York Academy of Sciences.

[61]  T. Iwatsubo,et al.  Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain , 2003 .

[62]  J. C. Greene,et al.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Julián Benito-León,et al.  Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain , 2003, Movement disorders : official journal of the Movement Disorder Society.

[64]  D. Twelves,et al.  Systematic review of incidence studies of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[65]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[66]  K. Østergaard,et al.  Steele‐Richardson‐Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein , 2002, Movement disorders : official journal of the Movement Disorder Society.

[67]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[68]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[69]  S. Tsuji,et al.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.

[70]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[71]  Seung-Jae Lee,et al.  Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form* , 2002, The Journal of Biological Chemistry.

[72]  K. Wada,et al.  Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia. , 2001, Human molecular genetics.

[73]  Joshua M. Shulman,et al.  Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles , 2001, Science.

[74]  N. Quinn,et al.  Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations , 2001, Neurology.

[75]  Takayuki Harada,et al.  Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice , 1999, Nature Genetics.

[76]  J W Langston,et al.  Parkinson disease in twins: an etiologic study. , 1999, JAMA.

[77]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[78]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[79]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[80]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[81]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[82]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[83]  A. Hofman,et al.  Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.